Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 13 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

7Total
Not Applicable (4)
Early P 1 (1)
P 2 (2)

Trial Status

Recruiting8
Not Yet Recruiting2
Unknown2
Withdrawn1

Clinical Trials (13)

Showing 13 of 13 trials
NCT07589595Phase 2Recruiting

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

NCT06596746Recruiting

Neurodegenerative Diseases Progression Markers (MARKERS-NDD)

NCT07790744Recruiting

A Comprehensive, Multimodal Characterization of Prodromal PD in Subjects With RBD

NCT06193252Not ApplicableRecruiting

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

NCT06993142Not ApplicableRecruiting

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

NCT07187843Recruiting

Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD

NCT07533799Recruiting

The Swedish BioFINDER Sleep Study

NCT07324330Not ApplicableRecruiting

Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity

NCT06827821Early Phase 1Not Yet RecruitingPrimary

Application of 18F-CP6A PET Imaging in Synucleinopathies

NCT05611372Phase 2Withdrawn

Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

NCT06534177Not Yet Recruiting

Digital Diagnostics and Intervention Services for Parkinson's Disease

NCT05486806Unknown

Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders

NCT05452655Not ApplicableUnknown

Intensive Multidisciplinary Rehabilitation and Biomarkers in Parkinson's Disease

Showing all 13 trials

Research Network

Activity Timeline